Clinical trials
Cancer Risk clinical trials
Below are recruiting cancer risk clinical trials, each written for real people, not researchers. We’re tracking 724 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06282588RecruitingPhase 2/Phase 3
Advanced imaging-guided treatment for high-risk prostate cancer
This trial uses a special PET scan (PSMA PET/CT) and a genetic test (Decipher) to decide the best treatment for high-risk prostate cancer that hasn't spread outside the pelvis. You'll receive standard radiation and hormone therapy, possibly with an extra drug (darolutamide).
Wilrijk, AntwerpAges 18 years+ - NCT07062016Recruiting
Studying high-risk endometrial cancer with blood and tissue tests
This trial studies tumor DNA in blood and tissue from people with aggressive endometrial cancer to better understand the disease. You donate samples during surgery and follow-up visits.
Rochester, MinnesotaAges 18 years+ - NCT03922893Recruiting
Finding inherited cancer gene markers in at-risk families
This study looks at DNA (genetic information) from people and families who may have an inherited risk for cancer. It aims to find new genetic markers that can help explain cancer risk and guide future care.
Basking Ridge, New JerseyAges Any age - NCT06085664RecruitingPhase 1/Phase 2
Immunotherapy before prostate cancer surgery
This trial tests a new immunotherapy drug (REGN5678) given before surgery to men with high-risk prostate cancer that hasn't spread. The goal is to see if the drug can shrink or control the cancer before the prostate is removed.
Houston, TexasAges 18 years+ - NCT05941520RecruitingPhase 2
Acolbifene vs low-dose tamoxifen to prevent breast cancer
This Phase 2 trial compares acolbifene and low-dose tamoxifen to see which better lowers breast cancer risk in premenopausal women at high risk. You would be followed with health visits, blood tests, and a breast tissue sampling procedure.
Duarte, CaliforniaAges 35 years+ - NCT06424275Enrolling by invitation
Prostate cancer screening trial for European men ages 50-69
This trial aims to raise awareness and screen for prostate cancer in men aged 50 to 69 across the European Union. You may be able to join if you have never been diagnosed with prostate cancer and haven't had a prostate biopsy or MRI in the last six months.
DublinAges 50–69 - NCT06680791Recruiting
Endometrial cancer study on recurrence prevention and lifestyle
This study looks at how your cancer type and daily habits might help prevent endometrial cancer from coming back. It only requires that you've had endometrial cancer and a hysterectomy.
PragueAges Any age - NCT07237256RecruitingPhase 3
Testing less chemo for HR+ HER2- breast cancer with ribociclib
This trial tests whether some people with hormone receptor-positive, HER2-negative early breast cancer can safely receive less chemotherapy when also taking the targeted drug ribociclib after surgery. You may qualify if you have a specific stage of breast cancer and are planning to take hormone therapy for at least 5 years.
AmiensAges 18 years+ - NCT06910956Recruiting
Finding high-risk patients for lung cancer screening using chest X-rays
This trial uses artificial intelligence to analyze chest X-rays and identify people who may be at high risk for lung cancer and could benefit from a CT screening scan. It's designed for current or former smokers aged 50 to 77 who have had a recent chest X-ray and are not already being checked for lung cancer.
Boston, MassachusettsAges 50–77 - NCT07168096Recruiting
Emotional health and decision-making in cancer patients
This study tracks how anxiety and depression change over time in people with solid tumors. It aims to find risk factors and improve supportive care, while also exploring how much patients understand about their prognosis and want to be involved in decisions.
Santander, CantabriaAges 18 years+ - NCT07311577RecruitingPhase 2
Trial of a drug combo for HER2-positive ovarian cancer
This trial tests a combination of disitamab vedotin, platinum chemotherapy, and bevacizumab as first treatment for high-risk ovarian cancer that has a protein called HER2. The goal is to see if this therapy helps control the cancer and keeps it from growing.
Nanjing, JiangsuAges 18–75 - NCT05806515RecruitingPhase 2
Carboplatin before surgery for high-risk BRCA prostate cancer
This trial tests giving the chemotherapy drug carboplatin before surgery to treat people with high-risk prostate cancer and an inherited BRCA1 or BRCA2 gene change. The goal is to shrink or control the cancer before an operation and improve outcomes.
Anchorage, AlaskaAges 18 years+ - NCT06791161Enrolling by invitation
Adjuvant therapy study for BRCA1/2 positive breast cancer
This study tests if additional treatment after surgery helps prevent breast cancer from returning. It is for people with hormone receptor-positive, HER2-negative breast cancer who have a BRCA1 or BRCA2 gene mutation and a high risk of recurrence.
Beijing, Beijing MunicipalityAges 18–75 - NCT03418961RecruitingPhase 3
Study of heart-risk management for metastatic HER2 breast cancer
This trial follows people with metastatic HER2-positive breast cancer who are at higher risk for heart damage while on HER2-targeted therapy. Some participants are randomly assigned to different monitoring/heart-protection approaches to see what best helps keep the heart safe.
Anchorage, AlaskaAges 18 years+ - NCT07061977RecruitingPhase 3
New cancer drug combo for advanced cervical cancer
This trial tests if giving the immunotherapy drug pembrolizumab before and after standard chemoradiation works better than the standard approach for people with high-risk cervical cancer that has spread locally.
Birmingham, AlabamaAges 18 years+ - NCT06651580Recruiting
Gene study for kids with pancreas problems
This study collects samples like blood or tissue from children with pancreatitis to look for gene changes that might raise their risk. It helps doctors learn more about why some children get pancreas inflammation.
Los Angeles, CaliforniaAges Up to 17 years - NCT05510934Recruiting
Thyroid cancer follow-up reminders for low-risk patients
This study tests a smartphone-based reminder system to help people with earlier-stage differentiated thyroid cancer stay on track for follow-up visits and testing. It may help catch problems sooner and make follow-up easier to manage.
Halifax, Nova ScotiaAges 18 years+ - NCT06689956Recruiting
Observation after surgery for low-risk endometrial cancer with tiny lymph node findings
This study looks at women with low-risk endometrial cancer who had tiny amounts of cancer cells found in their sentinel lymph nodes during surgery. Doctors want to see if it's safe to avoid additional treatments like chemotherapy or radiation.
Rochester, MinnesotaAges Any age - NCT06120387Recruiting
Radiation after kidney-sparing surgery for high-risk ureteral cancer
This trial tests whether adding radiation therapy after surgery that removes only part of the ureter or the entire kidney and ureter helps prevent cancer from coming back in patients who have high-risk features like aggressive cell type or deep tumor invasion.
BeijingAges 18 years+ - NCT06499870RecruitingPhase 2
Study of two drugs with radiation for high-risk prostate cancer
This trial tests whether combining two hormone therapy drugs, relugolix and enzalutamide, with radiation therapy can help treat very high-risk prostate cancer. The goal is to see if this combination is safe and effective for men whose cancer has a high chance of coming back.
Chicago, IllinoisAges 18 years+ - NCT03257969Recruiting
DROP program for patients starting oral cancer medicines
This trial studies whether a “DROP” support program helps ambulatory people with cancer manage drug-related problems when they start or change oral (by mouth) anticancer treatment. It may help reduce medication mistakes and complications by improving how you handle your regimen at home.
Pierre-BéniteAges 18 years+ - NCT04110756Recruiting
Program to help teens change health behaviors
This study tests a program designed to help teens make healthier choices. It’s for teens who are 15–17 and are currently drinking alcohol, who come to specific UCSF pediatric check-up visits.
San Francisco, CaliforniaAges 15–17 - NCT04290663RecruitingPhase 3
Radioiodine decision after thyroid surgery for intermediate-risk cancer
This study compares two approaches after thyroid surgery: giving radioactive iodine right away versus deciding based on follow-up test results. It aims to see which approach better helps people with intermediate-risk differentiated thyroid cancer.
Pointe à Pitre, GuadeloupeAges 18 years+ - NCT06237179RecruitingPhase 1/Phase 2
Exercise program to reduce heart risk in prostate cancer
This study tests whether a supervised exercise program can help reduce heart disease risk in men with prostate cancer who are on hormone therapy. Participants will exercise at home or in a group and be monitored for heart health changes.
Richmond, VirginiaAges 40–85
Hear when a new Cancer Risk trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for cancer risk?
- Yes. Clin2 currently lists 724 recruiting cancer risk studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a cancer risk trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a cancer risk trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.